资料单张
CARBILEV 25/100 Tablet
CARBILEV 25/250 Tablet
SCHEDULING STATUS:
S4
PROPRIETARY NAME
(and dosage form):
CARBILEV 25/100 Tablet
CARBILEV 25/250 Tablet
COMPOSITION:
Each Carbilev 25/100 tablet contains carbidopa monohydrate equivalent to 25 mg anhydrous
carbidopa
and 100 mg
levodopa
.
Each Carbilev 25/250 tablet contains carbidopa monohydrate equivalent to 25 mg anhydrous carbidopa and 250 mg
levodopa.
PHARMACOLOGICAL CLASSIFICATION:
A 5.4.1 Anti-Parkinsonism Preparations.
PHARMACOLOGICAL ACTION:
Carbilev 25/100 and Carbilev 25/250 contains carbidopa and levodopa.
Carbidopa, which does not cross the blood-brain barrier, inhibits the peripheral decarboxylation of levodopa, thus
slowing its conversion to dopamine in extracerebral tissues. This results in an increased availability of levodopa for
transport to the brain where it undergoes decarboxylation to dopamine, stimulating dopaminergic receptors in the basal
ganglia. This improves the balance between cholinergic and dopaminergic activity, resulting in improved modulation of
voluntary nerve impulses transmitted to the motor cortex.
INDICATIONS:
1. Treatment of Parkinson's disease and syndrome.
2. To reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with
levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration, peak dose dyskynesias,
akinesia, or similar evidence of short-duration motor disturbances.
CONTRAINDICATIONS:
Monoamine oxidase (MAO) inhibitors and Carbilev should not be given concurrently. It is recommended that MAO
inhibitors be discontinued at least two weeks prior to initiating Carbilev therapy.
Pregnancy and lactation. Carbidopa/levodopa combination has been associated with foetal abnormalities in animals, and
should therefore not be given to women of childbe
阅读完整的文件
资料单张 